Compare MWA & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWA | DNTH |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 2006 | 2018 |
| Metric | MWA | DNTH |
|---|---|---|
| Price | $25.24 | $107.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $30.50 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.0M | 857.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $1,429,700,000.00 | $2,036,000.00 |
| Revenue This Year | $4.78 | N/A |
| Revenue Next Year | $4.27 | $29.48 |
| P/E Ratio | $38.40 | ★ N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $22.74 | $18.08 |
| 52 Week High | $31.00 | $112.27 |
| Indicator | MWA | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 64.55 |
| Support Level | $25.11 | $79.27 |
| Resistance Level | $26.05 | N/A |
| Average True Range (ATR) | 0.58 | 5.96 |
| MACD | 0.05 | 0.53 |
| Stochastic Oscillator | 38.49 | 87.94 |
Mueller Water Products Inc is a U.S.-based company that manufactures and sells products and services used in the transmission, distribution, and measurement of water. The company operates in two segments: Water Flow Solutions and Water Management Solutions. The Water Flow Solutions segment, which derives maximum revenue for the company, includes products like iron gate valves, specialty valves, and service brass products. Water Management Solutions' portfolio includes fire hydrants, repair and installation, natural gas, metering, leak detection, and pressure management and control products and solutions. Geographically, the company derives a majority of its revenue from the United States and the rest from Canada and other international locations.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.